<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TOBRAFLEX- tobramycin and fluorometholone acetate suspension </strong><br>Alcon Pharmaceuticals<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1> DESCRIPTION</h1>
<p class="First"><span class="Bold">Tobraflex™</span> (tobramycin and fluorometholone acetate ophthalmic suspension, USP) is a sterile, multiple dose antibiotic and steroid combination for topical ophthalmic use. The chemical structures for tobramycin and fluorometholone acetate are presented below:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cbdf11f4-d84c-4c4a-aac2-f8c23304fb02&amp;name=Tobraflex-01.jpg"></div>
<p>                                                                                                                        Tobramycin<br>                                                                                                                        Empirical Formula: C<span class="Sub">18</span>H<span class="Sub">37</span>N<span class="Sub">5</span>O<span class="Sub">9</span><br>                                                                                                                        Chemical Name:<br>                                                                                                                        O-3-Amino-3-deoxy-α-D-glucopyranosyl-<br>                                                                                                                        (1-&gt;4)O-[2,6-diamino-2,3,6-trideoxy-<br>                                                                                                                        α-D-ribo-hexopyranosyl-(1-&gt;6)]-2-<br>                                                                                                                        deoxy-L-streptamine</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cbdf11f4-d84c-4c4a-aac2-f8c23304fb02&amp;name=Tobraflex-02.jpg"></div>
<p>                                                                                                                        Fluorometholone Acetate<br>                                                                                                                        Empirical Formula: C<span class="Sub">24</span>H<span class="Sub">31</span>FO<span class="Sub">5</span><br>                                                                                                                        Chemical Name:<br>                                                                                                                        9-Fluoro-11β, 17-dihydroxy-6α-<br>                                                                                                                        methylpregna-1,4-diene-3,20-<br>                                                                                                                        dione 17-acetate</p>
<p><span class="Bold">Each mL contains: Active: </span>Tobramycin 0.3% (3 mg) and Fluorometholone Acetate 0.1% (1 mg).</p>
<p><span class="Bold">Preservative: </span>Benzalkonium Chloride 0.01%. <span class="Bold">Inactive: </span>Tyloxapol, Edetate Disodium, Sodium Chloride, Hydroxyethyl Cellulose, Hydrochloric Acid and Sodium Hydroxide (to adjust pH), Purified Water. The pH range is 6.0 -7.0. DM-00</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1> CLINICAL PHARMACOLOGY</h1>
<p class="First">Corticoids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticoids may inhibit the body’s defense mechanism against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant. Clinical studies have demonstrated that Fluorometholone Acetate Suspension is a potent corticosteroid.</p>
<p>In clinical studies of documented steroid-responders, fluorometholone acetate demonstrated a significantly longer average time to produce a rise in intraocular pressure than dexamethasone phosphate; however, in a small percentage of individuals, a significant rise in intraocular pressure occurred within one week. The ultimate magnitude of the rise was equivalent for both drugs.</p>
<p>The antibiotic component in the combination (tobramycin) is included to provide action against susceptible organisms. In vitro studies have demonstrated that tobramycin is active against susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms: Staphylococci, including <span class="Italics">S. aureus </span>and <span class="Italics">S. epidermidis </span>(coagulase-positive and coagulase-negative), including penicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p>
<p>Streptococci, including some of the Group A beta-hemolytic species, some nonhemolytic species, and some <span class="Italics">Streptococcus pneumoniae.</span></p>
<p><span class="Italics">Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, </span>most <span class="Italics">Proteus vulgaris </span><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>, <span class="Italics">Haemophilus influenzae </span>and <span class="Italics">H. aegyptius, Moraxella lacunata, and Acinetobacter calcoaceticus (Herellea vaginacola) </span>and <span class="Italics">some Neisseria species.</span></p>
<p>Bacterial susceptibility studies demonstrate that in some cases microorganisms resistant to gentamicin remain susceptible to tobramycin. <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">Bacterial resistance</span> to tobramycin may develop upon prolonged use.</p>
<p>No data are available on the extent of systemic absorption from <span class="Bold">Tobraflex™</span> Ophthalmic Suspension; however, it is known that some systemic absorption can occur with ocularly applied drugs.</p>
<p>When a decision to administer both a corticoid and an antibiotic is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of both is administered, plus assured compatibility of ingredients when both types of drug are in the same formulation and, particularly, that the correct volume of drug is delivered and retained.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1> INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">Tobraflex™</span> Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or a risk of bacterial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> exists.</p>
<p>Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. They are also indicated in chronic <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">anterior uveitis</span> and corneal injury from chemical, radiation or <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">thermal burns</span>, or penetration of foreign bodies.</p>
<p>The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, tobramycin, is active against the following common bacterial eye pathogens: Staphylococci, including <span class="Italics">S. aureus </span>and <span class="Italics">S. epidermidis </span>(coagulase-positive and coagulase-negative), including penicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p>
<p>Streptococci, including some of the Group A beta-hemolytic species, some nonhemolytic species, and some <span class="Italics">Streptococcus pneumoniae.</span></p>
<p><span class="Italics">Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, </span>most <span class="Italics">Proteus vulgaris </span><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>, <span class="Italics">Haemophilus influenzae </span>and <span class="Italics">H. aegyptius, Moraxella lacunata, and Acinetobacter calcoaceticus (Herellea vaginacola) </span>and some <span class="Italics">Neisseria species.</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1> CONTRAINDICATIONS</h1>
<p class="First">Epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and many other viral diseases of the cornea and conjunctiva, <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">Mycobacterial infection</span> of the eye. Fungal diseases of ocular structures. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of the medication.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1> WARNINGS</h1>
<p class="First">NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. If a sensitivity reaction does occur, discontinue use.</p>
<p>Use of ocular steroids may prolong the course and may exacerbate the severity of many <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the eye. Prolonged use of steroids may result in <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, with damage to the optic nerve, defects in visual acuity and fields of vision, and <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation. If used for more than 10 days, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. In acute purulent conditions of the eye, steroids may mask <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or enhance existing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="P"></a><a name="section-7"></a><p></p>
<h1> PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2> General</h2>
<p class="First">The possibility of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the cornea should be considered after long-term steroid dosing. As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, appropriate therapy should be initiated. When multiple prescriptions are required, or whenever clinical judgement dictates, the patient should be examined with the aid of magnification such as slit-lamp biomicroscopy and, where appropriate, fluorescein staining.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2> Information For Patients</h2>
<p class="First">Do not touch dropper tip to any surface, as this may contaminate the suspension. Contact lenses should not be worn during the use of this product.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.3"></a><p></p>
<h2> Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No studies have been conducted to evaluate the carcinogenic or mutagenic potential. No impairment of fertility was noted in studies of subcutaneous tobramycin in rats at doses of 50 and 100 mg/kg/day. No studies of impairment of fertility by fluorometholone acetate are available.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.4"></a><p></p>
<h2> Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C. </span>Animal studies have not been conducted with <span class="Bold">Tobraflex™</span> Ophthalmic Suspension. Fluorometholone has been shown to be embryocidal and teratogenic in rabbits when administered at low multiples of the human dose. Fluorometholone was applied ocularly to rabbits daily on days 6 to 18 of gestation, and dose-related fetal loss and fetal abnormalities including <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, deformed rib cage, anomalous limbs and neural abnormalities such as <span class="product-label-link" type="condition" conceptid="432419" conceptname="Encephalocele">encephalocele</span>, craniorachischisis, and <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span> were observed. Reproduction studies have been performed in rats and rabbits with tobramycin at parenteral doses up to 100 mg/kg/day with no evidence of harm to the fetus (2000X the maximum recommended human dose). There are no adequate and well-controlled studies of <span class="Bold">Tobraflex™</span> Ophthalmic Suspension in pregnant women. <span class="Bold">Tobraflex™</span> Ophthalmic Suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.5"></a><p></p>
<h2> Nursing Mothers</h2>
<p class="First">Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when <span class="Bold">Tobraflex™</span> Ophthalmic Suspension is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.6"></a><p></p>
<h2> Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 2 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.7"></a><p></p>
<h2> Geriatic Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1> ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component, the anti-infective component, or the combination. Exact incidence figures are not available. The most frequent adverse reactions to topical ocular tobramycin (TOBREX® Ophthalmic Solution) are localized ocular toxicity and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, including lid <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and conjunctival <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>. These reactions occur in less than 4% of patients. Similar reactions may occur with the topical use of other aminoglycoside antibiotics. Other adverse reactions have not been reported; however, if topical ocular tobramycin is administered concomitantly with systemic aminoglycoside antibiotics, care should be taken to monitor the total serum concentration. The reactions due to the steroid component are: elevation of intraocular pressure (IOP) with possible development of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, and infrequent optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>; <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation; and delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">Secondary Infection</span>. </span>The development of <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span> has occurred after use of combinations containing steroids and antimicrobials. <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infections</span> of the cornea are particularly prone to develop coincidentally with long-term applications of steroids. The possibility of fungal invasion must be considered in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where steroid treatment has been used. Secondary bacterial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> following suppression of host responses also occurs.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1> DOSAGE AND ADMINISTRATION</h1>
<p class="First">One or two drops instilled into the conjunctival sac(s) every four to six hours. During the initial 24 to 48 hours, the dosage may be increased to one or two drops every two (2) hours. Frequency should be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to discontinue therapy prematurely.</p>
<p>Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in <a href="#P">PRECAUTIONS</a> above.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1> HOW SUPPLIED</h1>
<p class="First">Tobraflex™ is a sterile ophthalmic suspension supplied in Alcon's DROP-TAINER® package system.</p>
<p><span class="Bold">TobraFlex™</span> is supplied as either a 2.5 mL or a 5 mL fill in a 5 mL natural polyethylene dispenser bottle with a natural polyethylene dropper tip and a white polypropylene overcap. Tamper evidence is provided with a shrink band around the closure and neck area of the package.</p>
<p>2.5 mL - NDC 0065-0651-25</p>
<p>5 mL - NDC 0065-0651-05</p>
<div class="Section">
<a name="section-10.1"></a><p></p>
<h2> STORAGE</h2>
<p class="First">Store upright at 36° to 77°F (2° to 25°C) and shake well before using.</p>
<p><span class="Bold">Rx Only</span></p>
<p> U.S. Patent No. 5,149,693 </p>
<p>©2001 Alcon Laboratories, Inc.</p>
<p><span class="Bold">Alcon®</span></p>
<p><span class="Italics">PHARMACEUTICALS</span></p>
<p><span class="Bold">Alcon Laboratories, Inc.</span></p>
<p> Fort Worth,  Texas  76134</p>
<p>Printed in  USA</p>
<p>Rev: May 2001</p>
<p><span class="Bold">345351-0501</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TOBRAFLEX 		
					</strong><br><span class="contentTableReg">tobramycin and fluorometholone acetate suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0065-0651</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>tobramycin</strong> (tobramycin) </td>
<td class="formItem"></td>
<td class="formItem">3 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>fluorometholone acetate</strong> (fluorometholone) </td>
<td class="formItem"></td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>tyloxapol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydroxyethyl cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0065-0651-01</td>
<td class="formItem">1 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0065-0651-25</td>
<td class="formItem">2.5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0065-0651-05</td>
<td class="formItem">5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alcon Pharmaceuticals</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>527B6A76-1CA4-DC71-FC52-FE226633DFE8</div>
<div>Set id: cbdf11f4-d84c-4c4a-aac2-f8c23304fb02</div>
<div>Version: 1</div>
<div>Effective Time: 20060921</div>
</div>
</div> <div class="DistributorName">Alcon Pharmaceuticals</div></p>
</body></html>
